References
- Rodriguez-Gutierrez R, Gionfriddo MR, Ospina NS, et al. Shared decision making in endocrinology: present and future directions. Lancet Diabetes Endocrinol 2016; 4: 706–716
- Draznin B, Aroda VR, Bakris G, et al. American Diabetes Association Professional Practice Committee. 6. Glycemic targets: Standards of Medical Care in Diabetes—2022. Diabetes Care 2022; 45(Suppl. 1): S83–S96
- Marx N, et al. 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes; Eur Heart J 2023; 00: 1–98
- McDonagh TA, et al. 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure Eur Heart J 2023; 00: 1–13
- American Diabetes Association Professional Practice Committee. 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes-2024. Diabetes Care. 2024; 47(Suppl 1): S219-S230. doi:10.2337/dc24-S011
- Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Kidney Int. 2022; 102(4S): S1–S123.
- Упатство за практивување на медицина ба-зирана на докази за превенција, дијагноза и водење на преддијабете, дијабетес тип 2 во здравствени установи од областа на општа/ семејна медицина, Слижбен весник на РСМ, Стр. 28 - Бр. 170, 10.08.2023
- Алгоритам за рана дијагноза и следење на хронична бубрежна болест (ХББ) кај лица со тип 2 дијабетес (Т2Д); Подготвено од: Маке-донско здружение за нефрологија, трансплан-тација дијализа и вептачки органи, Научно здружение на ендокринилози и дијабетолози на Македонија, Македонско здружение за ме-дицинска биохемија и лабораториска меди-цина, Здружение на интернисти на РМ, Ма-кедонско здружение по кардиологија, јануари 2024, <https://www.mzndtvo.com.mk/>.
- Levin A, Tonelli M, Bonventre J, et al., ISN Global Kidney Health Summit participants. Global kidney health 2017 and beyond: a roadmap for closing gaps in care, research, and policy. Lancet. 2017;3 90: 1888–1917.
- de Boer I.H. et al; Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO) Kidney International (2022) 102, Issue 5, 974–989.
- .Levey AS, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009; 150: 604–12.
- Inker LA, Eneanya ND, Coresh J, et al. New Creatinine- and Cystatin C-Based Equations to Estimate GFR without Race. N Engl J Med. 2021; 385(19): 1737–1749.
- Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl. 2013; 3: 1–150.
- Sadusky T, Hurst C. The patient voice in health care decision making: the perspective of people living with diabetes and CKD. Clin J Am Soc Nephrol. 2021; 16: 991–992.
- Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2020 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Kidney International 2020; 98: S1–S115.
- de Boer IH, Bangalore S, Benetos A, et al. Diabetes and Hypertension: A Position Statement by the American Diabetes Association. Diabetes Care. 2017; 40(9): 1273–1284.
- Kidney Disease: Improving Global Outcomes (KDIGO) Blood Pressure Work Group. KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease. Kidney Int. 2021; 99(3S): S1–S87.
- Wanner C, Kidney Disease: Improving Global Outcomes Lipid Guideline Development Work Group Members. KDIGO clinical practice guideline for lipid management in CKD: summary of recommendation statements and clinical approach to the patient. Kidney Int. 2014; 85: 1303–1309.
- Sharp Collaborative Group. Study of Heart and Renal Protection (SHARP): randomized trial to assess the effects of lowering low-density lipo-protein cholesterol among 9,438 patients with chronic kidney disease. Am Heart J. 2010; 160: 785–794.e10.
- EMPA-KIDNEY Collaborative Group. Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial. Lancet Diabetes Endocrinol. 2024; 12(1): 39–50
- Htoo PT, Tesfaye H, Schneeweiss S, Wexler DJ, Everett BM, Glynn RJ, Schmedt N, Koeneman L, Déruaz-Luyet A, Paik JM, Patorno E. Cardio-renal effectiveness of empagliflozin vs. glucagon-like peptide-1 receptor agonists: final-year results from the EMPRISE study. Cardiovasc Diabetol. 2024 Feb 8; 23(1): 57.
- Heerspink HJL, Stefánsson BV, Correa-Rotter R, et al. Dapagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. 2020; 383(15): 1436–1446.
- Perkovic V, Jardine MJ, Neal B, et al., CREDENCE Trial Investigators. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy.N Engl J Med. 2019; 380: 2295–2306.
- Davies MJ, D’Alessio DA, Fradkin J, et al. Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2018; 61: 2461–2498.
- Gerstein HC, Colhoun HM, Dagenais GR, et al.; REWIND Investigators. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019; 394: 121–130.
- Hernandez AF, Green JB, Janmohamed S, et al.; Harmony Outcomes committees and investigators. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. Lancet. 2018; 392: 1519–1529.
- Mann JFE, Fonseca V, Mosenzon O, et al. Effects of liraglutide versus placebo on cardiovascular events in patients with type 2 diabetes mellitus and chronic kidney disease. Circulation. 2018;1 38: 2908–2918.
- Marso SP, Bain SC, Consoli A, et al.; SUSTAIN-6 Investigators. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016; 375: 1834–1844.
- Agarwal R, Filippatos G, Pitt B, et al. Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis [published correction appears in Eur Heart J. 2022 May 21; 43(20): 1989.